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Running title: mGlu5 signaling is altered in Shank3 KO mice 
Abstract 
SHANK3 (also called PROSAP2) genetic haploinsufficiency is thought to be the major cause of 
neuropsychiatric symptoms in Phelan-McDermid syndrome (PMS). PMS is a rare genetic disorder 
that causes a severe form of intellectual disability (ID), expressive language delays and other 
autistic features. Furthermore, a significant number of SHANK3 mutations have been identified in 
patients with Autism Spectrum disorders ASD, and SHANK3 truncating mutations are associated 
with moderate to profound ID. The Shank3 protein is a scaffold protein that is located in the 
postsynaptic density (PSD) of excitatory synapses and is crucial for synapse development and 
plasticity. In this study, we investigated the molecular mechanisms associated with the ASD-like 
behaviors observed in Shank3Δ11-/- mice in which exon 11 has been deleted. Our results indicate 
that Shank3 is essential to mediating mGlu5 receptor signaling by recruiting Homer1b/c to the PSD, 
specifically in the striatum and cortex. Moreover, augmenting mGlu5 receptor activity by 
administering 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) ameliorated the 
functional and behavioral defects that were observed in Shank3Δ11-/- mice, suggesting that 
pharmaceutical treatments that increase mGlu5 activity may represent a new approach for treating 
patients that are affected by PMS and SHANK3 mutations. 
 
 
Introduction 
SHANK3/PROSAP2 is considered to be the main gene that is associated with the neuropsychiatric 
symptoms experienced by patients with Phelan McDermid syndrome (PMS). PMS is characterized 
by a significant delay in expressive language, intellectual disability (ID), hypotonia, minor 
craniofacial dysmorphisms, increased tolerance to pain, epilepsy and autism-like features 1. 
Furthermore SHANK3 truncating mutations have been identified in patients with autism spectrum 
disorders (ASD) 2. ASD is a complex neurodevelopmental disorder that is defined by repetitive, 
restricted behavioral patterns and impaired sociability and communication. These neuropsychiatric 
conditions are probably due to the altered formation and plasticity of synaptic connections, which 
can lead to dysfunctional neuronal communication. Therefore, understanding the functions of 
Shank3 in the brain is crucial to developing new pharmacological targets with which to treat 
patients with Shank3 mutations or deletions. Indeed, several Shank3 KO mice were generated in 
which different regions of the gene were deleted 3-8. For a review, please see 9. 
Shank proteins (encoded by three genes, Shank 1−3) are scaffold proteins that are located in the 
postsynaptic density (PSD) of glutamatergic synapses. They are essential for dendritic spine 
development and plasticity. Overexpression of Shank1 in hippocampal neurons accelerated the 
maturation of filopodial−like protrusions in mature spines and promoted the enlargement of mature 
spines 10, 11. However, smaller dendritic spines, weaker synaptic transmission, and altered spatial 
learning have been observed in mice lacking Shank1 12. Shank3 overexpression in cerebellar 
granule cells induced dendritic spine and synapse formation by recruiting different subtypes of 
glutamate receptors, whereas inhibiting Shank3 expression in hippocampal neurons reduced the 
number of dendritic spines 13, 14. 
Shanks proteins, which are composed of five protein-protein interaction domains, including N-
terminal ankyrin repeats (ANK), a Src Homology 3 domain (SH3), a PDZ domain, a proline-rich 
region (Pro-rich), and a sterile alpha motif domain (SAM) at the C-terminus, interact with more 
than 30 synaptic proteins, including cytoskeletal proteins, cell adhesion proteins, and ionotropic and 
metabotropic glutamate receptors. A major complex is formed by interactions between the Pro-rich 
region of Shank with the EVH1 (Ena-VASP homology 1) domain of Homer proteins. Through this 
interaction and through the multimerization of Homer1b/c via its C-terminal coiled-coil domains, 
Shank stabilizes mGlu1 and mGlu5 at excitatory synapses and regulates its inositol-1,4,5-
trisphosphate receptor (IP3R)-mediated downstream pathway 15-18. 
Interestingly, the direct alteration of Homer1 and mGlu5 gene expression and function has been 
identified as a risk factor for ASD 19 , and different studies have linked Homer proteins to mGlu5 
receptor-mediated synaptic plasticity and ASD 20, 21. mGlu5 proteins are highly expressed 
postsynaptically in the cortex, striatum and hippocampus 22-24. 
Our previous studies demonstrated that in rat hippocampal cell cultures, mGlu5 receptor expression 
and function were strongly affected when Shank3 expression was downregulated using a specific 
shRNA 14. However, it is not clear whether in vivo Shank3 deletion caused these impairments in 
mGlu5 functions. 
In this study, we investigated the molecular mechanisms that are associated with the ASD-like 
behaviors observed in Shank3Δ11-/- mice, which were generated by deleting exon 11 and which are 
characterized by the absence of the three major and higher MW isoforms of Shank3 25. 
Our data indicate that, specifically in striatum and cortex, Shank3 performs an essential function in 
mediating mGlu5 receptor signaling by recruiting Homer1b/c to the PSD. Moreover, our results 
suggest that augmenting mGlu5 receptor activity using CDPPB ameliorated the functional and 
behavioral defects observed in Shank3Δ11-/- mice. 
 
Materials and Methods 
Mice 
The Shank3Δ11-/- mice were generated as previously described by Schemeisser et al. 25 and re-
derived in a C57BL/6 background (Charles River Laboratories, Calco, Italy). They were housed 
under constant temperature (22 ± 1°C) and humidity (50%) conditions with a 12 h light/dark cycle 
and provided with food and water ad libitum. Using heterozygous mice for breeding, we derived 
wild type and knockout littermates.  
 
Cell culture preparation and transfection of primary rat and mouse cortical neurons 
Rat cortical neuronal cultures were obtained from 18- to 19-day-old rat embryos as previously 
described, with minor modifications 11, 14. Neurons were grown in B27 medium that was prepared in 
the laboratory in 12- or 6-well petri dishes (Primo). 
Mouse cortical neurons were prepared from E18 embryos, grown in 12- or 6-well petri dishes 
(Primo) and maintained in Neurobasal B27-supplemented medium (Life Technologies). Rat cortical 
neurons were transfected using Lipofectamine 2000 on day 11 (DIV11), and the experiments were 
performed on DIV13-15. 
 
Immunocytochemistry and image analysis 
Mouse cortical neurons were fixed at DIV13 in 100% methanol at -20°C for 10 minutes. Rat 
cortical neurons were transfected at DIV 11 and fixed at DIV15 in 4% paraformaldehyde. Primary 
antibodies (anti-Homer1, provided by Enjoom Kim Laboratory, KAIST Institute, Sout Korea and 
anti-Bassoon, Enzo Life Sciences, cat. ADI-VAM-PS003-F) and secondary antibodies were applied 
in GDB Buffer in PBS (30 mM phosphate buffer, pH 7.4, 0.2% gelatin, 0.5% Triton X-100, and 0.8 
M NaCl; all from Sigma-Aldrich).  
Confocal images were obtained using a confocal microscope (Zeiss 510 Confocal Microscope, a 
gift from Fondazione Monzino) with a 63× objective and sequential-acquisition setting at a 
resolution of 1024 × 1024 pixels. A total of 16 neurons (cortical neurons fixed at DIV 15) for each 
genotype (WT and KO) were randomly chosen for quantification from 4 to 10 coverslips from three 
independent experiments. Morphometric measurements were performed using MetaMorph image 
analysis software. Colocalization was measured by using color-separating Homer and Bassoon 
channels, manually setting a threshold level for each channel (identical for each neuron), and then 
determining the overlapping area using MetaMorph analysis. 
Morphometric and colocalization analyses were performed by investigators who were blind to the 
experimental conditions. Measurements are expressed as the means ± SEM. 
For the immunodetection of postsynaptic density markers on brain sections, the mice were 
anesthetized intraperitoneally using Avertin (Sigma-Aldrich) and then decapitated. The brains were 
rapidly excised and manually cut into coronal slabs that were fixed via immersion in ice-cold 
paraformaldehyde (4% in 0.1 M phosphate buffer, PB, pH 7.4) for 30 min 26. After fixation, the 
tissue slabs were rinsed in PB, cryoprotected via immersion in ascending sucrose solutions (10%, 
20% and 30%), cut into 20-µm sections with a cryostat, mounted on gelatin-coated slides and stored 
for a maximum of one month at −20°C until immunolabeling was performed. Following blocking in 
normal donkey serum (NDS, 3% in PBS with 0.5% Triton X-100), the sections were incubated with 
primary antibodies diluted in PBS containing 3% NGS and 0.5% Triton X-100 overnight at 4°C 
(anti-PSD-95 NeuroMab, Ca, USA cat. 75-028 and anti-Homer1 provided by Enjoom Kim 
Laboratory, KAIST Institute, Sout Korea). The sections were then washed and incubated with 
secondary antibodies (cyanine-derived Cy3 anti-mouse, Alexa Fluor 488 anti-rabbit, both 1:1000; 
Jackson ImmunoResearch, West Grove, PA) that were diluted in 3% NGS and 0.5% Triton X-100 
in PBS for 1 hour at room temperature. The sections were rinsed again and coverslipped with Dako 
fluorescence mounting medium (Dako Italia, Italy). For quantitative analysis of Homer1-
immunoreactive puncta and colocalization studies, 5 serial optical sections (using a 0.5-µm Z-step 
size) were acquired from sections including layers 2-3 of the primary somatosensory cortex (S1), 
the CA1 region of the hippocampus (stratum radiatum) and the dorsal striatum (caudate and 
putamen nuclei) using a laser scanning confocal microscope (LSM5 Pascal; Zeiss) with a 100× 
objective (1.4 numerical aperture) and the pinhole set at 1 Airy unit. The density of the 
immunolabeled puncta was determined by manually counting postsynaptic clusters in neuropilar 
areas using dedicated software (Imaris, Bitplane, Zurich, CH) and expressed as puncta/100 µm2. 
 
Subcellular Fractionation and Western Blot analysis 
Subcellular fractionation of brain tissues was performed according to Distler et al., Proteomics, 
2014, with some modifications. All steps were performed at 4°C. In brief, tissues were 
homogenized in buffer A containing 0.32 M sucrose and 5 mM HEPES (pH7.4) and centrifuged at 
1.000 x g. The supernatant (S1) was further centrifuged at 12.000 x g, and a pellet containing the 
crude membrane fraction (P2) was obtained. This fraction was solubilized in buffer B containing 
0.32 M sucrose and 5 mM Tris (pH 8.1) and loaded onto a discontinuous sucrose step gradient (0.85 
M/1.0 M/1.2 M). After centrifugation at 85.000 x g, the synaptosomes (Syn) were collected from 
the 1.0 M/1.2 M interface and incubated with buffer C containing 0.32 M sucrose, 12 mM Tris (pH 
8.1) and 1% Triton X-100. After centrifugation at 32.800 x g, the PSD pellet was collected and 
solubilized in H2O. 
Equal amounts (10 µg) of each sample were separated using SDS-PAGE and subsequently blotted 
on nitrocellulose membranes according to standard protocols. Incubation with a primary antibody 
(β-actin Sigma, cat. A5316; Homer1b/c, SynapticSystems, cat. 160022,; mGluR5, Millipore, cat. 
AB5675; Shank3, Santa Cruz Biothecnology, cat. H-160; β3-tubulin, Covance, cat. PRB-435P ) 
was followed by treatment of the membrane with HRP-conjugated secondary antibodies (swine 
anti-rabbit, 1:1000 or rabbit anti-mouse, 1:3000; both Dako, Hamburg, Germany), and the signal 
was visualized using Pierce ECL Western Blotting Substrate and further detected using a 
MicroChemi 4.2 machine. All signals were quantified using Gel analyzer software 
(www.gelanalyzer.com/) and normalized against the values of the respective signal for β-actin.  
 
Immunoprecipitation Assay 
PSD-enriched preparations (as previously described) of different brain regions (cortex, 
hippocampus and striatum) from P60 WT and KO mice were incubated at 4°C overnight with 
protein A-Sepharose beads (GE Healthcare) conjugated to 10 μg/ml of Homer1b/c  (Santa Cruz cat. 
H-342) or of PSD-95 (NeuroMab, Ca, USA cat. 75-028 ) or control IgG (10 μg/ml) antibodies. The 
beads were then washed three times with RIPA buffer, re-suspended in sample buffer, warmed at 
65°C for 10 minutes and analyzed using SDS-PAGE. Western blot analysis was performed using 
mGlu5 (Millipore, cat. AB5675), SynGAP (Cell Signaling cat. D78B11) andGluN2A (Sigma cat. 
G9038) primary antibodies. 
 
FURA-2 Single Cell Ca2+ Imaging 
For Ca2+ measurements, 0.3 mln neurons were plated onto 24-mm round coverslips in 6-well plates. 
At DIV12-DIV14, the plates were loaded with 5 μM Fura-2 AM (Life Technologies, Milan, Italy) 
containing 0.002% Pluronic F-127 (Life Technologies) and 10 μM sulfinpyrazone (Sigma) in 
Krebs-Ringer modified buffer (KRB solution: 125 mM NaCl, 5 mM KCl, 1 mM Na3PO4, 1 mM 
MgSO4, 2 mM CaCl2 5.5 mM glucose, and 20 mM HEPES, pH 7.4) for 30 min at room temperature 
(RT). The neurons were then washed twice in KRB, and the Fura-2 was allowed to de-esterify for 
another 30 min at RT. The coverslips were then mounted in the acquisition chamber of a Leica 
DMI6000 epifluorescent microscope equipped with an S Fluor 40x/1.3 objective. First, neurons 
expressing a GFP-tagged shShank3 or control (shCtrl) plasmid were imaged and photographed 
using Leica AM Meta Morph software (Molecular Devices, Sunnyvale, CA, US) at an excitation 
wavelength of 488 with a bandpass 510-nm emission filter. The cells were then alternately excited 
at 340 and 380 nm using a monochromator Policrome V (Till Photonics, Munich, Germany), and 
images of the fluorescent signals were captured each second through bandpass 510 nm filter using a 
CCD camera (Hamamatsu, Japan). All hardware was controlled, and Fura-2 images were analyzed 
using MetaFluor (Molecular Devices) software. To quantify differences in the amplitudes of Ca2+ 
transients, the ratio values were normalized using the formula (DF)/F0 (referred to as norm. ratio). 
To compare multiple samples (e.g., shShank3 and rescue results), ANOVA was used with Tukey’s 
post-hoc tests. To analyze differences between two samples (e.g., Shank3-KO results) Student’s 
two-tailed unpaired t-tests were used. Differences were considered statistically significant when p < 
0.05.  
 
Electrophysiology 
Procedures were conducted in conformity with the European Communities Council Directive of 
November 1986 (86/609/ECC), in accordance with protocols approved by the Animal Care and Use 
Committee at the Universities of Perugia (Italy).  
Mice were sacrificed by cervical dislocation and coronal corticostriatal slices (250 μm) were cut in 
Krebs’ solution (in mM: 126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 10 glucose, 25 
NaHCO3) using a vibratome. The slices were maintained in Kreb's solution, bubbled with a O2 95% 
and CO2 5% gas mixture at room temperature 27. A single slice was transferred to a recording 
chamber and submerged in a continuously flowing Kreb’s solution (34°C, 2.5–3 ml/min) bubbled 
with a 95 % O2–5 % CO2 gas mixture. Whole-cell patch-clamp recordings were obtained from 
dorsolateral striatal neurons optically detected (Olympus) and electrophysiologically identified as 
MSNs 27. Whole-cell voltage-clamp (Vhold -80 mV) or current-clamp recordings were performed 
with borosilicate glass pipettes (4–7 MΩ; Ra 15–30 MΩ) filled with a standard internal solution 
containing (in mM): 125 K+-gluconate, 0.1 CaCl2, 2 MgCl2, 0.1 EGTA, 10 HEPES, adjusted to pH 
7.3 with KOH. Signals were amplified with a Multiclamp 700B amplifier (Molecular Devices), 
recorded and stored on PC using pClamp 10 (Molecular Devices). Membrane potentials and 
currents were recorded in the presence of 50 μM picrotoxin to block GABAA receptors. 
Glutamatergic excitatory postsynaptic currents (EPSCs) were evoked by a bipolar electrode 
connected to a stimulation unit (Grass Telefactor) and located in the white matter between the 
cortex and the striatum. Paired-pulse ratios of EPSC amplitudes (EPSC2/EPSC1) were obtained by 
a paired-pulse stimulation protocol at 50 ms inter-stimulus interval.  
Drugs were bath-applied by switching the perfusion solution to drug-containing solution using a 
three-way tap syringe. Total replacement of the medium in the chamber occurred within 1 minute. 
CDPPB, CHPG, DHPG, NMDA, muscarine, picrotoxin, L-SOP, were purchased from Tocris-
Cookson (Bristol, UK). CHPG, DHPG and muscarine were bath applied in the recording chamber 
alone and then co-applied with NMDA.  
Data analysis was performed off-line using Clampfit 10 (Molecular Devices) and GraphPad Prism 5 
(GraphPad Software). Values in the text and figures are mean ± SEM, n representing the number of 
recorded neurons. Student’s t-test was used for statistical analysis with a significance level 
established at p<0.05.  
 
Behavioral Assays 
For behavioral analyses, 3-month-old age-matched littermate mice were used. All experimental 
procedures followed the guidelines established by the Italian Council on Animal Care and were 
approved by the Italian Government. All efforts were made to minimize the number of animals used 
and their suffering. Shank-3-/- mice and their littermates were housed in cages in groups of five with 
free access to food and water at 22°C and with a 12-h alternating light/dark cycle. When obtaining 
behavioral profiles, the animals were tested once for each test. All tests were performed between 8 
a.m. and 2 p.m. 
Spontaneous motor activity  
Motor function was evaluated in an activity cage (43 × 43 × 32 cm) (Ugo Basile, Varese, Italy) that 
was placed in a sound-attenuating room as previously described 28. The cage was fitted with two  
horizontal and vertical infrared beams that were located 2 cm and 4 cm from the floor of the cage, 
respectively. Before the start of the test each mouse was habituated to the testing room for 1 h. 
Cumulative horizontal and vertical movement counts were recorded for 10 min.  
Repetitive self-grooming 
Spontaneous repetitive self-grooming behavior was scored as previously described 29. Each mouse 
was individually placed into a standard cylinder, (46 cm length × 23.5 cm wide × 20 cm high). 
Cylinders were empty to eliminate digging in the bedding, which is a potentially competing 
behavior. The room was illuminated at ~ 40 lux. A front-mounted CC TV camera (Security 
Cameras Direct) was placed at ~ 1 m from the cages to record the sessions. Sessions were video-
taped for 20 min. The first 10-min of habituation was not scored. Cumulative time spent grooming 
all the body regions during the second 10 min of the test session and the total number of grooming 
episodes was measured. 
Spatial object recognition 
Object location tests were performed in an arena according to the methods described in Kenney et 
al. 30, with slight modifications. Two visual cues were placed on two adjacent walls of an opaque 
white Plexiglas cage (58×50×43 cm) that was dimly lit from above (27 lux). The visual cues 
consisted of a black and white striped pattern (21×19.5 cm) that was affixed to the center of the 
northern wall and a black and gray checkered pattern (26.5×20 cm) that was placed in the center of 
the western wall. The objects were counterbalanced across locations. The cage and the objects were 
thoroughly wiped down with acetic acid (0.1%) before and after all behavioral procedures, which 
were observed and recorded using a camera mounted above the cage. Climbing or sitting on objects 
was not scored as object exploration. Mice that did not spend more than a total of 30 s exploring the 
objects during training or testing were excluded from the analysis. Mice were pre-exposed to the 
cage for 10 min. Twenty-four hours later, the mice were returned to the cage and allowed to explore 
two different objects placed in the NE and NW corners, and the time spent exploring the objects 
was recorded. Two hours later, the object the mouse had spent more time exploring in the previous 
session was moved to the SW corner of the cage (only this object was placed in the cage), and the 
mouse was allowed to re-explore the cage. Exploration was defined as a mouse having its nose 
directed toward the object and within approximately 1 cm of the object 31. Performance was 
evaluated by calculating a discrimination index (N-F/N+F), where N = the time spent exploring the 
moved object during T2, and F = the time spent exploring the stationary object during T2. 
Sociability and Preference for Social Novelty Tests 
The apparatus was a rectangular, three-chamber, transparent polycarbonate box (width = 42.5 cm, 
height = 22.2 cm, center chamber length = 17.8 cm, and side chamber lengths = 19.1 cm) as 
previously described 27. The test mouse was first placed in the middle compartment, and it was 
allowed to explore all three chambers for 10 min (habituation). Then, an unfamiliar adult DBA/2J 
male mouse was placed in one side compartment. The opposite side compartment contained an 
empty wire cage. The social novelty tests were performed in the same apparatus immediately after 
sociability test. The cages were not cleaned between these two tests. For these tests, one side 
compartment contained the familiar mouse (from the previous sociability phase), while the other 
side contained an unfamiliar mouse. The new, unfamiliar mouse was placed in the wire cage 
that had been empty during the prior 10-min session. The familiar and unfamiliar animals were 
from different home cages and had never been in physical contact with the subject mouse or with 
each other. For both tests, the time spent in each chamber and the number of entries into each 
chamber were recorded for 10 min. The data were expressed as the difference in the scores between 
the time spent exploring the compartment containing the familiar mouse and the time spent in the 
empty compartment (for sociability tests) or the difference in the scores between the time spent 
containing the stranger animal and the time spent with the familiar mouse (for social novelty 
tests). An operator blind to the genotypes of the mice manually recorded the time spent in each 
chamber. We also evaluated a sociability index (SI) and a social novelty preference index (SNI) as 
follows: SI = (time exploring novel mouse 1 – time exploring novel object) / (time exploring novel 
mouse 1 + time exploring novel object) and SNI = (time exploring novel mouse 2 – time exploring 
familiar mouse) / (time exploring novel mouse 2 + time exploring familiar mouse). 
Morris water maze test 
The Morris water maze test was used to analyze changes in the learning and memory abilities of the 
mice according to the methods described in Morris 32 (adapted for mice). A circular water maze 
(120 cm in diameter x 50 cm in height) was used. A circular hidden platform with a diameter of 10 
cm was placed inside the maze, and its surface was maintained at 0.5 cm below the surface of the 
water. Floating plastic particles were placed on the surface of the water to hide the platform from 
sight according to the methods of Zhang et al. 33. The temperature of the water was 25.0°C ± 0.5°C. 
For the habituation trials, the mice were placed in a random area inside the maze and allowed to 
swim for 60 sec. For the acquisition trials, the mice were submitted to 4 trials per day (with 60 sec 
inter-trial intervals) for 4 consecutive days during which each mouse was released into the pool at 
different starting points and trained to locate a constant platform position. At 24 hours after the last 
trial, a probe test was performed during which the platform was removed. Two days later, a reversal 
task was performed to assess cognitive flexibility. The platform was placed in the opposite quadrant 
of the tank, and 4 daily trials were performed for 4 days. On the fifth day, a probe trial was 
performed that was similar to that in the acquisition phase. The time spent in the target area and the 
latency to reaching the target zone were evaluated by an experimenter who was blind to the 
genotypes of the mice. After each trial, the mice were placed on a paper towel to dry, and they were 
then placed back into their home cages. 
T-maze test  
Mice were deprived of food until they reached 85–90% of their free-feeding body weight. They 
were habituated to a black wooden T-maze (with a 41-cm stem section and a 91-cm arms section). 
Each section was 11 cm wide and had walls that were 19 cm high. The mice were habituated to the 
T-maze and trained to obtain food within the maze for 5 days as previously described 28. During the 
acquisition phase, one arm was designated the reinforcer (Coco Pops; Kellogg’s) in each of ten 
daily trials. Each mouse was placed at the start of the maze and allowed to freely choose which arm 
to enter. The number of days required to reach the goal criterion (80% correct for 3 days) was 
recorded. Each mouse that met the goal for acquisition was then tested using a reversal procedure in 
which the reinforcer was switched to the opposite arm. 
 
Pharmacological Treatment 
CDPPB (Tocris) was dissolved in DMSO and polyethylene glycol 400 (DMSO:PEG 400 = 1:9) for 
the in vivo experiments and in DMSO only for the in vitro experiments. Wild-type and Shank3Δ11-
/- mice received an intraperitoneal injection of the CDPPB (3 mg/kg)-containing solution or the 
same volume of a DSMO:PEG400 mixture 70 min before each behavioral test. 
 
iPSC generation and differentiation into neurons 
Fibroblasts obtained from patients diagnosed with Phenal-McDermid syndrome were collected 
according to a clinical protocol approved by the local Bioethical Committees of different medical 
centers. Participating individuals were informed of the objectives of the study and were required to 
sign an informed consent document before inclusion into the study. The deletion of 22q13.3 was 
confirmed in two of the PMS patients using genetic analysis. The detailed procedures used for the 
generation, maintenance, and characterization of iPS cells were previously described in 34. For 
immunofluorecence experiments were used the following primary antibodies: Nanog (Abcam cat. 
AB80892), Oct3/4 (Santa Cruz Biotechnology cat. sc-5279), Sox2 (Proteintech cat. 11064-1-AP), 
MAP2 (Abcam cat. AB11268), Synaptophysin (Sigma MS5768). 
 
Data analysis 
All of the behavioral, electrophysiological and imaging experiments and all data analyses were 
performed under blinded conditions in which the persons performing the experiment and the 
persons performing the analysis used a random numerical code, which was produced and known by 
another person, to label the differed samples. 
 
Statistics 
For all graphic data, n indicates number of biological replicates. The n values are reported in the 
Figure Legends and/or in the Results paragraph describing the experiments. All quantitative 
biochemical data are representative of three independent experiments, and all behavioral data are 
representative of at least two experiments. The sample size for biochemical, morphological Ca2+ 
imaging and electrophysiological experiments was determined by empirical evidence accumulated 
in our laboratory and also on previous literature. For behavioral test the number of mice was chosen 
to ensure adequate power a on the basis of the program G*power 3.1 (Charan et al., J Pharmacol 
Pharmacother 4(4): 303-306, 2013), available on line : http://www.gpower.hhu.de/.  
Based on the number of comparisons and the pattern of data distribution, appropriate statistical tests 
were used to analyze the data. Unpaired two-tailed t-test was used to evaluate the difference 
between two groups; the variances in two groups were similar in all data sets. Two-way analysis of 
variance followed by post hoc test was used for comparison of multiple samples. Significance was 
set at P<0.05. All values are presented as mean ± SEM. 
 
Results 
Deletion of Shank3 in mice results in ASD-like behavior 
To determine whether a Shank3 mutation in mice results in ASD-like behavior and ID, we 
characterized the behavior of Shank3Δ11-/- mice (previously called ProSAP2/Shank3αβ-/- in 25). 
To analyze repetitive, stereotyped behavior, which is one of the two cores symptoms of ASD, we 
measured grooming behaviors. In KO mice, we detected an increase in self-grooming activity in 
terms of the time spent grooming and the number of grooming episodes (Figure 1A).  
Given that impaired social interaction is the second core symptom of ASD, we tested sociability in 
Shank3Δ11-/- mice using a three-chamber test (Figure 1B). We observed that KO mice were 
impaired in that they spent more time exploring the compartment containing the empty cage than 
the compartment containing the stranger mouse (left panel). In addition, KO mice remained closer 
to the familiar stranger for longer period of time, which suggests impaired social recognition (right 
panel). Accordingly, the corresponding sociability index (SI) and the social novelty preference index 
(SNI) scores were lower in the KO mice than in their littermates. Because SHANK3 mutations are 
often associated with ID, we tested spatial learning and memory in Shank3Δ11-/- mice. To evaluate 
spatial memory, we used a spatial object recognition test in which we analyzed a discrimination 
index with an inter-trial interval of 120 min. We did not detect significant differences between the 
two genotypes in this test (Figure 1C). 
We also tested the mice in a water-maze place navigation task. KO mice showed normal acquisition 
compared to their littermates (Figure 1D left panel). Spatial memory was then tested using a probe 
trial, which was administered after a 4-day training period during which we measured the latency 
(Figure 1D, center panel) and the time required to reach the target quadrant (Figure 1D, right 
panel). We did not detect any significant difference between the genotypes. The latency and the 
percentage of time spent swimming to the target quadrant were also not significantly different. On 
the contrary, the escape latency of KO mice was longer than the latency in WT mice on day 8 and 
day 9 (Figure1E, left panel). In the probe trial, the KO mice took longer to find the target zone 
(Figure 1E, center panel) and spent less time than WT mice to swim to the quadrant that 
previously housed the platform (Figure1E, right panel). Shank3Δ11-/- mice also showed 
impairments in the T-maze task, but only during the reversal phase (Figure1F). KO mice required 
more days to achieve the criterion than WT mice. This resistance to change in a learned pattern of 
behavior indicates that Shank3Δ11-/- mice recapitulate cognitive rigidity, which is a typical 
symptom of many neuropsychiatric disorders, including ASD. 
We next analyzed behaviors related to avoidance of inanimate objects and restricted interests. In the 
marble burying test, KO mice buried fewer marbles than WT mice and took a larger amount of time 
to bury the first marble (Supplementary Figure 1A). We detected a similar pattern in avoidance 
behavior when we measured nest building in that KO mice had lower nest building scores than WT 
mice (Supplementary Figure 1B). The corresponding AUC (Supplementary Figure 1C) was 
significantly lower in KO mice than in WT mice. These results strongly suggest that Shank3Δ11-/- 
mice exhibit restricted interest and an avoidance phenotype when exposed to inanimate objects. 
We next characterized motor coordination and motor learning, behaviors that are also often altered 
in ASD patients, in Shank3Δ11-/- mice. Fine motor coordination and balance were assessed using the 
beam walking assay. We did not observe any difference in the mean time required to cross to the 
escape box between the two genotypes (Supplementary Figure 1D). On the contrary, during the 
pole test, KO mice took longer to complete the task than WT mice (Supplementary Figure 1E) 
and they had more difficulty in remaining suspended from the lid during the hanging wire test 
(Supplementary Figure 1F). In rotarod tests, KO mice showed a defect only in the fourth trial of 
the first day of evaluation (Supplementary Figure 1G). These data indicate that Shank3Δ11-/- mice 
exhibit only minor deficits in motor coordination. 
Because there is a strong association between anxiety and autism, we also tested Shank3Δ11-/- mice 
using an elevated plus maze, but we did not find any differences between WT and KO animals 
(Supplementary Figure 1H). 
Associated symptoms, which have also been documented in a subset of individuals with ASD, 
include increased aggression and hyposensitivity to pain. Indeed, we found that aggressive behavior 
was significantly increased in KO mice compared to WT mice (Supplementary Figure 1I) and that 
KO mice showed a higher mean threshold latency than WT mice in hot plate tests (Supplementary 
Figure 1L). 
Interestingly, we also tested Shank3Δ1+/- mice, and we did not observe any major behavioral 
impairment except for a longer time to complete the pole test than was observed in WT mice 
(Supplementary Table 1).  
 
Shank3 absence alters the synaptic localization of Homer and the mGlu5 receptor  
Based on our previous results that showed that knock-down of Shank3 in primary neuronal cultures 
caused a significant reduction in the mGlu5 receptor 14, we measured mGlu5 and Homer1b/c 
protein levels in total homogenates and PSD fractions from the striatum, cortex and hippocampus of 
Shank3Δ11-/- mice.  
In PSD fractions obtained from KO animals, we observed a reduction in Homer1b/c protein levels 
in the striatum, a reduction in both mGlu5 and Homer1b/c in the cortex, and no change in mGlu5 
and Homer1b/c levels in the hippocampus (Figure 2A). Interestingly, decreased mGlu5 receptor 
and Homer1b/c levels were detected only in the PSD fractions, and there was no significant change 
in the level of either protein in total homogenates (Supplementary Figure 2A). These biochemical 
data indicate that in vivo, Shank3 absence alters mGlu5 receptor and Homer 1b/c protein 
expression only in the PSD of specific brain regions.  
To understand whether the localization of Homer was altered in the absence of Shank3, we next 
analyzed postsynaptic Homer1 signals in the dorsal striatum, in layers 2-3 of the primary 
somatosensory cortex and in the CA1 stratum radiatum of the hippocampus in Shank3Δ11-/- mice 
using immunofluorescence and confocal microscopy. First, we found that the density of Homer1-
positive puncta was unchanged between WT and Shank3Δ11-/- mice in all three brains regions 
(Figure 2B and Supplementary Figure 2B). Interestingly, KO mice showed an increase in the 
density of Homer1 puncta that did not colocalize with PSD-95 and, in parallel, a robust reduction in 
double-labeled puncta in both the dorsal striatum and the somatosensory cortex (Figure 2B and 
Supplementary Figure 2B). In contrast, we did not observe any change in Homer1 localization in 
the CA1 area of the hippocampus in KO mice (Figure 2B and Supplementary Figure 2B).  
We then examined whether these alterations in the synaptic localization of Homer1 compromised 
the interaction between Homer and the mGlu5 receptor by performing co-immunoprecipitation 
assays using tissues from the striatum, cortex and hippocampus. 
Quantitative analysis using WB was performed to co-immunoprecipitate mGlu5 using Homer1b/c 
antibodies. The results revealed a significant reduction in protein-protein interactions between 
mGlu5 and Homer1b/c in both the striatum and the cortex, but not in the hippocampus, in 
Shank3Δ11-/- mice compared to WT mice (Figure 2C). We also co-immunoprecipitated SynGAP 
and GluN2A using PSD-95 antibodies in the striatum, cortex and hippocampus of Shank3Δ11-/- and 
WT mice. Quantitative analysis of corresponding blots showed that there was no difference in the 
interaction between PSD-95 and SynGAP or PSD-95 and GluN2A between Shank3Δ11-/- and WT 
mice in any the brain areas analyzed. These results confirm that the absence of Shank3 specifically 
reduced mGlu5/Homer interactions in the striatum and cortex (Supplementary Figure 2C). 
Finally, in consideration for the results obtained in the different brain areas, we next sought to 
determine whether Shank3 levels were different in the striatum, cortex and hippocampus in total 
homogenates and PSD fractions, and we found that its expression was lower in the hippocampus 
(Supplementary Figure 2D) 
Taken together, these data suggest that the absence of Shank3 causes brain region-specific 
alterations in both protein levels and the localization of the mGlu5 receptor and Homer1b/c at 
synapses and that these changes prevent the normal formation of the mGlu5/Homer complex, which 
is essential to mediating mGlu5 intracellular signaling35-37. 
To clarify whether Homer1b/c localization was altered also in neurons derived from patients with 
PMS who exhibited SHANK3 haploinsufficiency, we established human induced pluripotent stem 
cell (hiPSC) lines using cells derived from two different patients with PMS, one of whom had a 
deletion of approximately 7.99 Mb (Patient 1) and one of whom had a deletion that was 22q13.3 
ARSA-negative (Patient 2). As a control, we used hiPSCs that were generated from two healthy 
donors. The control and PMS clones were tested to determine the expression of endogenous 
pluripotency markers (Supplementary Figure 3A-B). The hiPSC clones were differentiated into 
cortical neurons via the generation of neural-rosette intermediate neural progenitors, and they were 
subsequently differentiated for 80 days. We confirmed using WB that there was a reduction in 
Shank3 protein levels in the neurons obtained from both of the PMS patients compared to the 
Shank3 levels in the control (Supplementary Figure 3C). To analyze Homer cluster localization, 
we infected neuronal progenitors with a lentivirus expressing Homer-GFP. Interestingly, after 80 
days of differentiation, we observed a significant reduction in the number of Homer puncta that co-
localized with Synaptophysin in neurons derived from both of the PMS patients compared to the co-
localization observed in the neurons derived from the controls (Figure 2D). These results suggest 
that in human neurons, Shank3 is essential for Homer1b/c synaptic localization. 
 
Shank3 absence impairs the mGlu5-mediated intracellular release of calcium  
Shank/Homer1b/c protein interactions play a major role in mediating mGlu5 intracellular signaling 
by linking the mGlu5 receptor to IP3 receptors (IP3Rs) 10, 15-17, 38-41.  
We therefore investigated whether elimination of Shank3 altered the generation of mGlu5 
receptor-mediated Ca2+ signals in cortical neurons isolated from Shank3Δ11-/- mice. First, we 
confirmed that the reduction in the mGlu5 receptor and Homer1b/c protein levels that was 
observed in the cortex was also observed in the synaptic fractions of cultured cortical neurons 
obtained from Shank3Δ11-/- mice (Figure 3A). Then, we measured the induction of Ca2+ transients 
by 200 µM DHPG, a specific group I metabotropic receptor agonist. Figure 3B shows that DHPG-
induced Ca2+ transients in KO neurons were significantly lower than in WT neurons, indicating that 
the elimination of the Shank3 protein impaired mGlu5-mediated signaling in cortical neurons. To 
confirm that these alterations in calcium signaling mediated by mGlu5 receptor activation were 
due to alterations in the synaptic distribution of Homer, we analyzed the synaptic localization of 
Homer1b/c using immunofluorescence in cultured cortical neurons that were derived from 
Shank3Δ11-/- and WT mice. Quantification of the co-localization of Homer puncta and Bassoon 
revealed that the postsynaptic localization of Homer was reduced in the Shank3Δ11-/- cortical 
cultured neurons (Figure 3C).  
In a second series of experiments, we knocked down Shank3 using specific shRNA sequences. 
Supplementary Figure 4A–B shows that the administration of 200 µM DHPG elicited a much 
lower Ca2+ transient in shRNA-Shank3-tranfected neurons than in control neurons (either non-
transfected or transfected with a GFP-expressing plasmid) (Supplementary Figure 4A-B). When 
the shShank3-resistant form of Shank3 was co-expressed with the shRNA-Shank3 plasmid, the 
DHPG-induced Ca2+ transients were restored to control levels, indicating that the effect of shRNA-
Shank3 transfection was specific. We also confirmed using immunofluorescence that Homer-
Bassoon co-localization was altered in Shank3 knock-down neurons (Supplementary Figure 4C). 
Our previous results suggested that in vitro, the reduction in mGlu5 receptor activity that was 
caused by Shank3 knock-down could be rescued using CDPPB, a positive allosteric modulator of 
mGlu5 receptor  14, 42. For these experiments, DIV12-14 cortical neuronal cultures were loaded with 
Fura-2 and challenged with 200 μM DHPG in either the presence (5 min of preincubation, Figure 
3D) or the absence of 3 μM CDPPB. As expected, in the Shank3Δ11-/- cortical neurons, the DHPG-
induced Ca2+ transients were approximately 40% lower than in the WT neurons. After 
preincubation with CDPPB, the Ca2+ transients in the Shank3Δ11-/- neurons were significantly 
augmented, reaching the level of WT neurons (Figure 3D). 
 
The effect of mGlu5 stimulation on NMDA responses in striatal medium spiny neurons is 
dependent on Shank3 
Because we observed a disruption in synaptic Homer localization in the absence of Shank3 and high 
expression of Shank3 in the striatum, we tested the electrophysiological properties of striatal 
neurons. 
Patch-clamp recordings were obtained using medium spiny neurons (MSNs) obtained from WT and 
KO mice to explore whether the deletion of Shank3 affected the basal membrane properties of 
striatal neurons. Current-voltage curves were obtained by delivering hyperpolarizing and 
depolarizing steps of currents to the MSNs of KO (n=6) and WT (n=6) mice, and we observed no 
difference between these two groups of neurons, suggesting that the basal membrane properties of 
MSNs do not depend on Shank3 expression (Figure 4 A-B).  
We subsequently studied whether Shank3 was responsible for the observed changes in the 
membrane potential and the ionic currents induced by the stimulation of group I mGlu receptors in 
MSNs. Activation of these types of metabotropic glutamate receptors has been shown to enhance 
the membrane depolarization/inward current that is produced by the activation of the NMDA 
receptor in striatal MSNs 43. As shown in Figures 4C and 4G, the application of 30 µM NMDA 
produced a membrane depolarization of approximately 15 mV and an inward current of 
approximately -70 pA in MSNs in WT mice, while the co-application of NMDA in the presence of 
DHPG produced a significantly larger depolarization (Figure 4C-D) and inward current (Figure 4 
G-H). Interestingly, in the MSNs obtained from KO mice, the co-application of NMDA plus DHPG 
failed to produce a membrane depolarization and inward current that was larger than those observed 
in the presence of NMDA alone (Fig. 4E-H). 
Because mGlu5 receptors are mainly involved in potentiation of NMDA  responses in striatal 
MSNs 44, we also tested whether the selective mGlu5 receptor agonist CHPG would be able to 
increase NMDA receptor-mediated responses in MSNs obtained from WT and KO mice. 
As shown in Supplementary Figure 4A-B, when 500 µM CHPG was applied for 5 minutes, it 
significantly enhanced the NMDA receptor-mediated membrane depolarization of MSNs (n=5) 
obtained from WT mice, but it failed to produce a larger NMDA response in the MSNs obtained 
from KO animals (n=5). Taken together, these data confirm that in striatal MSNs, normal NMDA 
receptor function depends on mGlu5 receptor activity, and this interplay is essentially disrupted 
by the deletion of Shank3.  
We also explored whether Shank3 is involved in the functions of a different class of metabotropic 
receptors, the muscarinic cholinergic receptors. Because in MSNs, the NMDA receptor-mediated 
response is increased by the activation of muscarinic cholinergic receptors 43, we tested whether 
Shank3 also plays a role in this process (Supplementary Figure 4C-D). Interestingly, we found 
that activating cholinergic receptors using muscarine increased NMDA-mediated neuronal 
depolarization in MSNs obtained from both WT and KO mice. These experiments confirm that 
Shank3 does not play a major role in mediating metabotropic responses that are related to the 
activation of cholinergic receptors in MSNs. 
Finally, we tested whether Shank3 was involved in the function of presynaptic group III mGlu 
receptors. In fact, stimulating mGluIII receptors is known to inhibit glutamate release and 
excitatory postsynaptic currents (EPSCs) in MSNs via a presynaptic mechanism of action. Thus, we 
first tested the effect of applying a 10 µM solution of the mGlu III receptor agonist L-SOP to 
MSNs for 10 minutes. We found that the EPSC amplitude was reduced by 34.72 ± 8.2% (n=4, 
p<0.05) and 47.9 ±5.9% (n=6, p<0.05) in WT and KO mice, respectively (Supplementary Figure 
4E-F). Moreover, we measured the effect of L-SOP on paired-pulse facilitation (PPF) because 
changes in PPF are indicative of a presynaptic mechanism of action. As shown in Supplementary 
Figure 4F, PPF (EPSC2/EPSC1) was significantly increased in MSNs obtained from both WT and 
KO animals in the presence of L-SOP. These results substantiate the hypothesis that Shank3 
deletion specifically affects mGlu5 signaling in striatal MSNs. 
We then tested the effect of CDPPB on MSNs obtained from WT and KO mice, and as shown in 
Figures 4I-J, CDPPB treatment was able to recover normal NMDA receptor functions, which 
depend on mGlu5 receptor activity, in the MSNs obtained from Shank3 KO mice to levels 
comparable to those in the MSNs obtained from WT mice. 
Surprisingly, we found that, in Shank3 KO MSN, CDPPB alone was able to rescue the activation of 
NMDA receptor mediated responses; on the contrary, in culture cortical neurons from Shank3 KO 
mice, CDPPB alone was not able to rescue the impaired calcium release (data not shown). Thus we 
cannot exclude neither that in MSN CDPPB has also a partial intrinsic agonist activity nor that in 
striatal slices preparation the glutamate tone is higher then in cultured neuronal preparation and it is 
enough to partially activate mGlu5. 
 
The mGlu5 receptor positive agonist CDPPB rescues ASD-like behavior in Shank3Δ11-/- mice 
Because CDPPB was able to rescue the functional defects observed in both cortical and striatal 
neurons, we tested whether the behavioral abnormalities observed in Shank3Δ11-/- mice could be 
pharmacologically ameliorated by treating KO mice with CDPPB 45, 46. 
The behavioral profiles of KO mice were evaluated after treatment with CDPPB (3 mg/kg i.p.) or 
vehicle (veh), which was administered acutely or repeatedly 70 min before each test. The results are 
reported in Figure 5. The increased self-grooming activity observed in KO mice was reduced by 
acute treatment with CDPPB (Figure 5B). There was also a significant reduction in the mean 
number of grooming episodes. Notably, the drug did not affect motor activity when mice were 
evaluated immediately after self-grooming activity (Figure 5A). Reduced sociability (Figure 5C, 
left) was slightly, but not significantly, rescued in KO animals by acute treatment with CDPPB 
when analyzed as time spent close to the stranger/object. However, the SI, which measures sniffing 
activity, was significantly increased when the animals were given CDPPB. Social recognition was 
completely rescued in Shank3Δ11-/- mice, when analyzed as either the time spent close to the 
stranger2/stranger1 or sniffing activity (Figure 5C, right). In the water-maze place navigation task 
(Figure 5D), the KO mice showed normal acquisition compared to WT mice in terms of mean time 
required to reach the platform. A significant latency reduction between the first and the fourth trial 
was observed in all groups (Figure 5D, left panel), suggesting a normal progression of learning. 
During the probe test, no difference among the groups was shown in latency (Figure 5D, center 
panel) or the time spent in the target zone (Figure 5D, right panel). During reversal (Figure 5E), a 
significant difference in the escape latency across the trials was observed. KO mice treated with 
vehicle were completely impaired compared to their littermates, while CDPPB reduced escape 
latency during the learning phase (Figure 5E, left panel). 
When submitted to the probe trial on day 10, the KO mice that were treated with CDPPB required 
less time to find the target zone (Figure 5E, center panel) and spent more time than the KO mice 
treated with vehicle to swim to the quadrant that previously housed the platform (Figure 5E, right 
panel). 
All of these pharmacological data demonstrate that the positive allosteric modulation of the mGlu5 
receptor was able to rescue the behavioral deficits observed in the Shank3Δ11-/- mice that resulted 
from altered mGlu5 signaling. 
 
Discussion 
To evaluate the role of Shank3 in synapse function and to develop therapies that might ameliorate 
or even reverse the neuropsychiatric symptoms experienced by patients with PMS or other 
mutations in the SHANK3 gene, we characterized the behavioral, molecular and 
electrophysiological phenotypes of Shank3 mutant mice that were generated by deleting exon 11 25. 
Among the Shank3 mutants that were available, Shank3Δ11-/- mice are less often studied, although 
they are highly homologous to the Shank3B-/- mutants described by Peça et al., 4.  
Behaviorally, our analysis demonstrates that the Shank3Δ11-/- mutant is an excellent model for 
studying the role of Shank3 in the pathogenesis of PMS and ASD. Indeed, this mutant line shows 
repetitive and stereotyped behavior, restricted interests and impaired social interactions, which are 
the core diagnostic features of ASD and are similar to the features observed in most other Shank3 
KO mice (see Figure 1). In addition, our mice, similar to the Shank3D4-9-/- mice, displayed 
impairments in the reversal phase of the Morris Water maze and T-maze tests 3-7, 25, 47-49. Because 
PMS patients are heterozygous for Shank3 mutations/deletions, we also tested all of the behavioral 
tasks in Shank3Δ11-/+ mice, but we did not find any significant behavioral defects in the 
heterozygous mice. Our results are in line with the results described in the majority of studies that 
have been performed using other Shank3 KO mice, in which it has been demonstrated that 
behavioral alterations are present only in Shank3 KO mice. It is possible that there are unknown 
compensatory mechanisms that reduce the severity of the Shank3 deletion in the heterozygous 
mice.   
The results of our molecular studies further indicate that Shank3 plays a major role in modulating 
mGlu5 signaling by regulating Homer recruitment/localization to the PSD in brain regions that are 
highly associated with ASD-like behavior 50-52. 
Finally, our findings demonstrate that treatment with a PAM for mGlu5 rescued both the functional 
and the behavioral defects observed in the Shank3Δ11-/- mutants. 
 
Deletion of Shank3 alters the recruitment of Homer to the PSD in the cortex and striatum  
Shank proteins are indirectly connected to group I mGlu receptors by Homer proteins, which 
contain coiled-coil domains. For Shank1, it has already been demonstrated that the Shank/Homer 
complex regulates their reciprocal localization at the PSD 11, 38. The biochemical and morphological 
data in this study demonstrate that in Shank3Δ11-/- mice, the localization of Homer1b/c to the PSD 
is significantly reduced in both striatal and cortical neurons. As consequence, the synaptic 
association of Homer1b/c and mGlu5 in these two areas is reduced (see Figure 2).  
Biochemical analysis of synaptosome preparations from the cortex, hippocampus and striatum of 
Shank3Δ11-/- mice have already shown that there is a significant increase in GluN2B in the 
hippocampus and a slight reduction in various AMPA receptor subunits in all of the regions 
analyzed 25. Here we specifically investigated mGlu5 and Homer protein levels based on our 
previous work showing a reduction in the expression of mGlu5 in Shank3 knock-down neurons 14. 
Importantly, both mGlu5 and Homer1b/c were reduced in the PSD fractions obtained from the 
cortex and striatum of Shank3Δ11-/- mice, while their expression in hippocampus was unaffected.  
Thus, our data indicate that depending on the brain region, Shank3 performs different functions at 
synapses. Even if the underlying molecular mechanism is not yet clear, biochemical analyses in 
several other Shank3 mutant mice have suggested that the brain region-specific function of Shank3 
in regulating glutamate receptor levels at synapses might further depend on the different splice 
variants that are expressed. For example, Shank3B-/- mutants exhibited a major reduction in GluA2, 
GluN2A and GluN2B in striatal PSDs 4 and Shank3e4-9 mutants exhibited a reduction in GluA1 in 
whole forebrain PSDs 3, 5. These alterations were not evaluated in Shank3Δ11-/- and Shank3ΔC/ΔC 
mice. In contrast, Shank3ΔC/ΔC mice showed a strong increase in mGlu5 in hippocampal PSD 
preparations 7. A common alteration observed in several Shank3 mutants is a reduction in Homer, 
as has been observed in forebrain PSDs of Shank3e4-9 5 mutants and in the striatal PSDs of Shank3B-
/- mutants 4.  
However, a systematic molecular analysis of each brain region of interest and how it is correlated to 
the regional expression level of all three Shank proteins and their isoforms alike has yet to be 
performed to decipher the defects in the highly complex synaptic transmission identified in Shank 
mutants. Finally, Homer1b/c synaptic localization is strongly impaired in hiPSC-derived neurons 
that were obtained from patients with PMS who exhibited SHANK3 haploinsufficiency, suggesting 
that Shank3 is also important for the normal clustering of Homer1b/c into synaptic puncta in human 
neurons (Figure 2D).  
 
Deletion of Shank3 alters mGlu5 function in cortex and striatum, but not in hippocampus 
Because mGluR-Homer complex formation is required for the correct function of mGluRs 53, we 
have provided in vitro data showing that mGlu5-dependent Ca2+ release from intracellular stores is 
impaired in cortical neurons in Shank3Δ11-/- mice (Figure 3B). We also provide in vivo data 
showing that mGlu5-dependent NMDA receptor potentiation is completely abolished in striatal 
neurons obtained from Shank3Δ11-/- mice (Figure 4). To the contrary, we did not observe any 
defects in DHPG-mediated LTD in the hippocampus in Shank3Δ11-/- mice (Supplementary Figure 
6).  The function of Shank3 in regulating mGlu5 signaling is specifically supported by the 
following data sets: 1) The expression of shRNA-resistant Shank3 rescued the changes in DHPG-
induced Ca2+ release from intracellular stores observed in Shank3 knock-down cortical neurons 
(Supplementary Figure 4A-B); 2) Shank3 does not play a major role in mediating metabotropic 
responses related to the activation of cholinergic receptors in MSNs and is not involved in the 
regulation of presynaptic group III mGluRs (Supplementary Figure 5); 3) CDPPB induced the 
positive modulation of mGlu5 activity and rescued the functional defects observed in both cortical 
and striatal neurons in Shank3Δ11-/- mice to WT levels (Figure 3D and Figure 4I-J) 
These results suggest that altered group I mGluR signaling could be one of the most common 
impaired synaptic signaling pathways in the Shank3 mutant brain. 
 
ASD-like behaviors were reversed in Shank3 mutant mice by an mGlu5 PAM. 
Our data are in line with recent evidence linking Homer proteins to mGlu5 receptor-mediated 
synaptic plasticity and ASD 21. Indeed, inhibiting mGlu5-Homer complex formation impaired 
mGluR-dependent LTD and protein synthesis in normal mice 53, while in a mouse model of Fragile-
X syndrome (FXS), mGlu5 receptors were less associated with Homer1b/c and more associated 
with Homer1a 20, 53, resulting in alterations in the cross-linking activity of Homer1b/c 38. Similarly, 
in a mouse model of Angelman Syndrome, mGlu5 receptor-dependent synaptic plasticity was 
altered because it showed an increased association with Homer 1b/c 54. However, in these two 
mouse models, an enhancement in hippocampal mGlu5 receptor function was the core phenotype 53, 
54, which was contrary to the decrease in mGlu5 receptor function we observed in Shank3Δ11-/- 
mutants. This indicates that changes in the function of synapses might occur if mGlu5 signaling is 
pathologically modified in any direction. Interestingly, Homer1 itself has recently been identified as 
a novel risk gene for non-syndromic ASD 55, and another study showed that mGlu5 gene expression 
was reduced in the dorsolateral prefrontal cortex (DLPFC) in ASD patients 19. 
Our previous findings prompted us to test whether the ASD-like behaviors of Shank3Δ11-/- mutants 
could be reversed by the application of an allosteric mGlu5 agonist, such as CDPPB. Indeed, we 
found that repetitive and stereotyped behavior, a lack of cognitive flexibility and partially impaired 
social interactions were rescued by in vivo treatment with CDPPB (Figure 5). A similar approach 
was used to rescue behavioral phenotypes in a Shank2 mutant line 56. Importantly, the potential of 
positive allosteric mGlu5 modulation has already been tested in other models of ASD. In particular, 
Auerbach et al. demonstrated that treatment with CDPPB restored synaptic and behavioral deficits 
in Tsc2+/− mutant mice 57, and very recently, Lin et al. showed that the systemic administration of 
CDPPB ameliorated the behavioral defects observed in Sarm1 knockdown mice 58. Our data, 
including our observation that there were no alterations in mGlu5 signaling in the hippocampus, 
suggest that the ASD-like behavioral defects that are the result of mGlu5 signaling impairments in 
the striatum and cortex of Shank3Δ11-/- mice can be functional rescued by CDPPB, even if we 
cannot totally exclude the possibility that CDPPB might have an effect on other brain areas. 
Our results confirm that positive allosteric modulation of mGlu5 antagonizes ASD-like behaviors 
and suggest that mGlu5 activity could be viewed as a potential therapeutic target for 
neurodevelopmental disorders in general, as has been suggested by many recent studies 59. 
Therefore, our findings open up new possibilities for the pharmacological treatment of patients 
affected by PMS and SHANK3 mutations. 
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Figure legends  
Figure 1. Deletion of Shank3 in mice results in ASD-like behaviors. A) Self-grooming behavior 
was evaluated as the time spent grooming (left) and the total number of grooming episodes 
(right). B) Differences in scores obtained for time spent in the chamber associated with the never 
seen before mouse and the empty cage (left) or the familiar mouse (preference for social novelty 
test) (right). C) Spatial memory was evaluated by determining a discrimination index in the spatial 
object recognition test. D-E) Acquisition and reversal in the Morris water maze was analyzed to 
determine learning patterns (left), escape latency to the target zone (center) and the time spent in the 
quadrant (right). F) Performance in the T maze test was analyzed as the number of days required to 
reach the criterion during the acquisition and reversal phases. 
Data are shown as the mean ± SEM of 10 animals for each group. *, p<0.05, **, p<0.01;  compared 
to the corresponding WT mice; $$, p<0.01 compared to the corresponding WT mice on the same 
day; &&, p<0.01 compared to the same genotype on day 1. Student’s t-tests or two-way Anova 
followed by Bonferroni tests were used for statistical analysis. 
 
Figure 2. Shank3 absence alters Homer and mGlu5 receptor synaptic localization. A) Protein levels 
of metabotropic glutamate receptor 5 (mGlu5) and Homer1b/c were analyzed using Western Blot 
analysis in postsynaptic density (PSD) fractions obtained from tissues in the striatum cortex and 
hippocampus of wild-type (WT) and Shank3Δ11-/- mice. Protein levels were each normalized 
against the respective PSD-95 and ratios were compared between genotypes. The results are shown 
as bar diagrams, and representative blots are shown below. All data are presented as the mean ± 
SEM; all P-values were derived using unpaired, two-tailed Student’s t-tests; *, p<0.05; **, p<0.01. 
Analyses are based on a sample size of n=6 animals for each group (WT and KO). B) 
Representative confocal micrographs showing PSD-95 (red) and Homer1 (green). Co-labeled 
puncta (arrowheads) are visible in high magnification images. The images show 
immunofluorescence puncta in the neuropil of the dorsal striatum, layer 2-3 of the primary 
somatosensory cortex and in the CA1 of the hippocampus in Shank3Δ11-/- and KO mice. The results 
are shown as bar diagrams. Data are presented as mean ± SEM. * p<0.05; ** p<0.01. Analyses are 
based on a sample size of n=6 animals for each group (WT and KO). Scale bars: 3 μm. C) PSD-
enriched preparations of the striatum cortex and hippocampus were obtained from three P60 WT 
and KO mice and subjected to an in vitro immunoprecipitation assay using rabbit Homer1b/c 
antibodies. The immunoprecipitated proteins were revealed after immunoblotting using rabbit 
mGlu5 and Homer1 antibodies. A rabbit IgG antibody was used as the negative control. The data 
are expressed as the mean ± SEM of three independent experiments and we used n=2 animals for 
each group (WT and KO) and experiment. *, p<0.05. D) The panels show representative images of 
hNP-derived neurons and dendrites from control and PMS patients, which, after infection with a 
lentivirus expressing Homer-GFP, were differentiated in neuronal differentiation medium for 80 
days. The staining (right panel) shows that GFP-Homer1b clusters in iPSC-derived neurons 
colocalize with the presynaptic marker Synaptophysin. Scale bar 10μm The results are shown as bar 
diagrams. The data are presented as the mean ± SEM of three independent experiments and we used 
n=2 independent hNP for each individuals. *, p<0.05.  
 
Figure 3. Shank3 absence impairs mGlu5-mediated intracellular calcium release in cortical 
neurons. Cortical neuronal cultures were prepared from WT and Shank3Δ11-/- E17-E18 mouse 
embryos. A) Western blot analysis of PSD-enriched fractions of cortical primary neurons obtained 
from WT and Shank3Δ11-/- mice at DIV15. Protein levels were each normalized against the 
respective actin control. Data are expressed as the mean ± SEM of n=3 independent cultures by 
genotype. *, p < 0.05. B) At DIV14-15 neurons were loaded with Fura-2 AM (5 µM, 30 min). After 
20 min of de-esterification, the neurons were challenged with 200 µM DHPG. The results are 
shown as bar diagrams. Representative traces of Ca2+ transients are shown at the left, and the data 
are expressed as the mean ± SEM of n=127 WT neurons and n=151 KO neurons that were 
registered from 18 coverslips (for each genotype) in three independent cultures. *, p<0.05; **, 
p<0.01. C) Representative images of WT and Shank3Δ11-/- mouse primary cortical neurons at 
DIV15. Confocal images were obtained using a Confocal Microscope with a 63x objective and with 
sequential-acquisition set at a resolution of 1024 x 1024 pixels. A total of 16 WT and Shank3Δ11-/- 
primary cortical neurons at DIV15 were randomly chosen for quantification from 4 to 10 coverslips 
from three independent experiments. Colocalization measurements were performed using 
MetaMorph image analysis software. Scale bar 5μm . The histogram shows the mean ± SEM for the 
area of Homer clusters over the area of Bassoon clusters and the area of Homer clusters NOT over 
Bassoon clusters. *, p < 0.05. D) At DIV12-14 cortical neurons were loaded with Fura-2 and 
challenged with 200 μM DHPG either in presence (5 min preincubation) or in absence of of 3 μM 
CDPPB. Results are shown as bar diagrams. Representative traces of Ca2+ transients are shown left; 
data are expressed as mean ± SEM of n=86 WT neurons and n=77 KO neurons with vehicle and of 
n=96 WT neurons and n=95 KO neurons with CDPPB registered from 18 coverslips (for each 
conditions) in three independent cultures for genotype. * p < 0.05; ** p < 0.01. 
  
Figure 4. The mGluR5-mediated enhancement of NMDA-induced neuronal responses is impaired 
in striatal medium spiny neurons of Shank3Δ11-/- mice A) Representative voltage traces show 
neuronal responses to hyperpolarizing and depolarizing current steps that were delivered to a striatal 
medium spiny neuron (MSN) in either a wild-type (WT) or a Shank3Δ11-/- (KO) mouse. B) The 
current-voltage plot for the MSNs that were recorded from WT and KO mice show that there was 
no difference between the two groups of mice (p>0.05), analyses are based on a sample size of n=5 
animals for each group (WT and KO). C, E) Voltage traces for MSNs that were recorded from WT 
(C) and a KO (E) mice show that the voltage responses when a 30 µM NMDA bath was applied to a 
striatal slice for 30 seconds under control conditions or in the presence of 50 µM of the mGluRI 
agonist DHPG for 5 minutes and after DHPG washout. D, F) Histograms show the NMDA-induced 
membrane depolarizations of MSNs recorded from WT (D) and KO (F) mice that were produced 
under control conditions, after 5 minutes of DHPG application, and following DHPG washout. ** 
p<0.01, analyses are based on a sample size of n=5 animals for each group (WT and KO). G) 
Current traces for two MSNs that were recorded from a WT (left) and a KO mouse (right) show the 
inward current that was produced when 30 µM NMDA was applied for 30 seconds under control 
conditions or in the presence of 50 µM DHPG. H) A histogram showing the NMDA-mediated 
inward current of MSNs from WT (left) and KO mice (right) in the presence of DHPG as a 
percentage of the response measured in the presence of NMDA alone. * p<0.05, analyses are based 
on a sample size of n=5 animals for each group (WT and KO). I) Voltage traces of two MSNs 
recorded from a WT (top) and a KO mouse (bottom) showing the voltage response produced by 
NMDA application in control condition and in the presence of 10 µM of the mGluR5 selective 
allosteric agonist CDPPB. J) Histogram showing the NMDA-mediated voltage response of MSNs 
from WT and KO mice in the presence of CDPPB as a percentage of the response measured in the 
presence of NMDA alone. Plot shows that there was no difference between the two groups of mice 
(p>0.05), analyses are based on a sample size of n=5 animals for each group (WT and KO) 
 
Figure 5. The mGlu5 receptor positive agonist CDPPB rescues ASD-like behavior in Shank3Δ11-/- 
mice. The behavioral profiles of Shank3Δ11-/- mice were evaluated after treatment with CDPPB (3 
mg/kg i.p.) or vehicle (veh), which were administered acutely or chronically at 70 min before each 
test. A) Mean horizontal (left) and vertical (right) movements were recorded for 10 min in an 
automated activity cage immediately after grooming recording. B) Self-grooming behaviors were 
evaluated as the time spent grooming (left) and the total number of grooming episodes (right) after 
acute treatment with CDPPB or vehicle. C) Differences in the scores corresponding to the time 
spent in the chamber associated with the never-seen-before mouse and the empty cage (left) or the 
familiar mouse (preference for social novelty test) (right). D-E) Acquisition and reversal tasks in 
the Morris water maze were performed after daily treatments for the duration of the task during 
both acquisition and reversal in mice administered CDPPB or vehicle to analyze learning patterns 
(left), escape latency to the target zone (center) and the time spent in the quadrant (right) during the 
probe test. The data are shown as the mean ± SEM of n=13 animals for each group. *, p< 0.05; **, 
p<0.01 compared to the corresponding WT mice; $$, p<0.01  compared to the corresponding 
Shank3Δ11-/- mice that were treated with vehicle; #, p<0.05 and ##, p<0.01 compared to the 
Shank3Δ11-/- mice that were treated with CDPPB. &, p<0.05 and &&, p<0.01 compared to the same 
genotype on day 1 (two-way Anova followed by Bonferroni test). 
 
Supplementary Figure 1. A) Number of marbles buried (left) and latency time (sec) (right) to the 
first burial. B-C) Nest building: the data are shown as the score and the calculated area under the 
curve (AUC). Motor coordination and muscular strength were tested using: D) balance beam tests, 
E) pole tests, F) wire-hanging tests and G) rotarod tests. H) Anxiety-like behavior was tested in the 
elevated plus maze as the number of open arm entries (including time) and total arm entries 
(including time). I) Aggressive behavior is expressed as the total number of attacks against the 
intruder and the latency to the first attack. L) Pain thresholds (sec) were evaluated using a hot plate 
test. n=15 animals for each genotype. *, p<0.05 and **, p<0.01 vs WT (Student’s t-test or two-way 
ANOVA followed by Bonferroni Test).  
 
Supplementary Figure 2. A) Protein levels of metabotropic glutamate receptor 5 (mGlu5) and 
Homer1b/c were analyzed using Western Blot analysis in total lysates obtained from tissues 
including the striatum, cortex and hippocampus of wild-type (WT) and Shank3Δ11-/- (KO) mice. 
Protein levels were normalized against the respective actin control, and ratios were compared 
between genotypes. The results are shown as bar diagrams, and representative blots are shown 
below. All data are presented as the mean ± SEM, and all P-values were derived from unpaired, 
two-tailed Student’s t-tests. *, p<0.05 and **, p<0.01. Analyses are based on a sample size of n=6 
animals for both WT and KO. B) Representative confocal micrographs of PSD-95 (red) and 
Homer1 (green). Immunofluorescence puncta in in the neuropil of the dorsal striatum, layer 2-3 of 
the primary somatosensory cortex and in the CA1 of the hippocampus of Shank3Δ11-/- WT and KO 
mice. C) PSD-enriched preparations of striatum cortex and hippocampus from P60 WT and KO 
mice were subjected to an in vitro immunoprecipitation assay using mouse PSD-95 antibody. The 
immunoprecipitated proteins were revealed after immunoblotting using rabbit SynGAP and 
GluN2A antibodies. Rabbit IgG antibody was used as a negative control. The data are expressed as 
the mean ± SEM of three independent experiments and we used n=2 animals for each group (WT 
and KO) and experiment. p>0.05. D) Protein levels of Shank3 were analyzed by Western Blot 
analysis in total homogenates (left) and PSD-enriched fractions (right) of hippocampus, striatum 
and cortex of WT mice. Protein levels were each normalized against the respective actin control. 
Results are shown as bar diagrams, representative blots are shown below. Analyses are based on a 
sample size of n=6 animals. 
 
Supplemantary Figure 3. A-B) Representative images of established clones of hiPSC colonies. All 
selected clones are positive for pluripotency markers as shown by immunofluorescence, panel A, 
and PCR, panel B. C), Western blot of Shank3 protein in neurons obtained from NPC of control 
and PMS patients differentiated for 80 days. Patient 1, left; Patient 2 right.  
 
Supplemantary Figure 4 A) Primary rat cortical neurons were prepared from E18-E19 mouse 
embryos at DIV11 and transfected with the following combinations of plasmids: GFP and FUW 
control vector (GFP+FUW); shShank3 plasmid and control FUW vector (shSh3+FUW); GFP and 
Shank3 full-length mutated to be resistant to shShank3 14 (GFP+Sh3FL), and shShank3 plasmid 
plus Shank3 full-length (shSh3+Sh3FL). At DIV14-15, the neurons were loaded with Fura-2 AM (5 
µM, 30 min) and stimulated with 200 µM DHPG. Representative traces of DHPG-induced Ca2+ 
transients are shown. B) Both GFP-expressing (Transfected) and non-transduced (non Transfected) 
neurons were selected for analysis. Data are expressed as the mean ± SEM of n=30 neurons for 
each transfection and condition from 6 to 20 coverslips per condition from four independent culture 
preparations. *, p<0.05 and **, p<0.01. C) Representative images of rat cortical neurons that were 
transfected with shCtrl (control vector) and shShank3 constructs at DIV11 and fixed at DIV15. 
N=18 primary rat neurons for each condition were randomly chosen for quantification from 4 to 10 
coverslips from three independent experiments. Colocalization measurements were performed using 
MetaMorph image analysis software. The histogram shows the mean ± SEM of the area of Homer 
clusters over the area of Bassoon clusters and the area of Homer clusters NOT over area of Bassoon 
clusters. **, p<0.01 
 
Supplementary Figure 5.  
A) Voltage traces for two MSNs that were recorded from a WT (left) and a KO mouse (right) show 
the voltage response that was produced by the application of NMDA under control conditions or in 
the presence of 500 µM of the mGluR5 selective agonist CHPG. B) A histogram showing the 
NMDA-mediated voltage responses for MSNs from WT (left) and KO mice (right) in the presence 
of CHPG as a percentage of the response measured in the presence of NMDA alone. *P<0.05, 
analyses are based on a sample size of n=5 animals for each group (WT and KO). C) 
Representative voltage traces of MSNs recorded from a WT (left) and a KO mouse (right) showing 
the membrane depolarization produced by 30 µM NMDA (30 seconds) in control condition and in 
the presence of 3 µM of the muscarinic receptor agonist muscarine (15 minutes). D) The histogram 
show the effect of NMDA application on the membrane potential of MSNs of WT (left) and KO 
(right) mice in control condition and in the presence of muscarine. *P<0.05, analyses are based on a 
sample size of n=5 animals for each group (WT and KO). E) Representative EPSC traces and 
histograms showing the reduction in the synaptic response that was produced by 10 µM of the 
mGluRIII agonist L-SOP in MSNs from WT and KO mice. *P<0.05, analyses are based on a 
sample size of n=5 animals for each group (WT and KO). F) Superimposed pairs of traces and 
histograms show the enhancement in the paired pulse ratios (EPSC2/EPSC1) that was produced by 
the application of L-SOP to MSNs that were recorded in slices obtained from WT and KO mice. *, 
P<0.05, **, P<0.01, analyses are based on a sample size of n=5 animals for each group (WT and 
KO). 
 
Supplementary Figure 6 
Experiments were performed in hippocampal brain slices obtained from n=6 animals for each group 
(WT and KO). The plot shows normalized field EPSP amplitudes before and after bath application 
of DHPG (100 µM) for 15 min. Cells were recorded in the stratum radiatum of the CA1 region of 
the hippocampus following stimulation of the Schaffer collaterals. 
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